|Application ||IHC-P, FC, WB, E|
|Calculated MW||26671 Da|
|Antigen Region||104-132 aa|
|Other Names||Endothelial protein C receptor, Activated protein C receptor, APC receptor, Endothelial cell protein C receptor, CD201, PROCR, EPCR|
|Target/Specificity||This CD201 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 104-132 amino acids from the Central region of human CD201.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CD201 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Binds activated protein C. Enhances protein C activation by the thrombin-thrombomodulin complex; plays a role in the protein C pathway controlling blood coagulation.|
|Cellular Location||Membrane; Single-pass type I membrane protein.|
|Tissue Location||Expressed strongly in the endothelial cells of arteries and veins in heart and lung, less intensely in capillaries in the lung and skin, and not at all in the endothelium of small vessels of the liver and kidney|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PROCR (CD201) is a receptor for activated protein C, a serine protease activated by and involved in the blood coagulation pathway. The protein is an N-glycosylated type I membrane protein that enhances the activation of protein C. Mutations in its gene have been associated with venous thromboembolism and myocardial infarction, as well as with late fetal loss during pregnancy.
Menschikowski,M., Exp. Cell Res. 315 (15), 2673-2682 (2009)
Nayak,R.C., Blood 114 (9), 1974-1986 (2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.